PHASE II STUDY OF GEFITINIB AND INSERTED CISPLATIN PLUS DOCETAXEL AS A FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING AN EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION

被引：0

作者：

Ohe, Yuichiro ^{[1
]}

Kanda, Shintaro ^{[2
]}

Horinouchi, Hidehito ^{[2
]}

Fujiwara, Yutaka ^{[2
]}

Nokihara, Hiroshi ^{[2
]}

Yamamoto, Noboru ^{[2
]}

Sekine, Ikuo ^{[3
]}

Kunitoh, Hideo ^{[4
]}

Kubota, Kaoru ^{[5
]}

Tamura, Tomohide ^{[2
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr Hosp, Dept Thorac Oncol, Chiba, Japan

[3] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan

[4] Mitsui Mem Hosp, Tokyo, Japan

[5] Nippon Med Sch, Div Med Oncol, Tokyo, Japan

来源：

关键词：

EGFR mutation; gefitinib; platinum-doublet chemotherapy; non-small-cell lung cancer;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.10-016

引用

页码：S867 / S867

页数：1